U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH).

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101.

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024.

Chugai Pharmaceutical revealed Phase III LUMINESCE trial results for their drug Enspryng (satralizumab).

FDA Approves NMD Pharma's IND Application for Phase 2b Trial of NMD670 in US Myasthenia Gravis Population.

Molecure S.A. is dedicated to finding new treatments for diseases once thought incurable, focusing on small-molecule and mRNA-based drugs. The company is now conducting a Phase II trial of their drug OATD-01 for active pulmonary sarcoidosis.

Mission Therapeutics has initiated a pivotal study on MTX325, which could potentially alter the progression of Parkinson’s Disease.

FDA Clears Italfarmaco's Duvyzat™ (givinostat) for Treatment of Duchenne Muscular Dystrophy.

Vertex has received authorization from the FDA to proceed with clinical trials for VX-407, a new drug candidate targeting the management of ADPKD.

Sosei Heptares reclaims complete control over HTL0027477 from GSK, a pioneering oral GPR35 activator set for clinical trials in treating inflammatory bowel conditions.

ACELYRIN, INC. has revealed encouraging initial data from its Phase 1/2 studies for Lonigutamab. This first-of-its-kind, injectable treatment targeting IGF-1R has shown promising therapeutic effects in patients suffering from Thyroid Eye Disease.

Entera Bio Unveils Strong Drug Absorption Results for Innovative Oral GLP-2 Hormone Pill Designed for Individuals with Short Gut Condition.